These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35166171)

  • 1. Using the ATN system as a guide for the neuropsychological assessment of Alzheimer's disease.
    Florean I; Penolazzi B; Menichelli A; Pastore M; Cattaruzza T; Mazzon G; Manganotti P
    J Clin Exp Neuropsychol; 2021 Nov; 43(9):926-943. PubMed ID: 35166171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers.
    Baldeiras I; Silva-Spínola A; Lima M; Leitão MJ; Durães J; Vieira D; Tábuas-Pereira M; Cruz VT; Rocha R; Alves L; Machado Á; Milheiro M; Santiago B; Santana I
    J Alzheimers Dis; 2022; 90(1):419-432. PubMed ID: 36120784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal change in ATN biomarkers in cognitively normal individuals.
    Ebenau JL; Visser D; Kroeze LA; van Leeuwenstijn MSSA; van Harten AC; Windhorst AD; Golla SVS; Boellaard R; Scheltens P; Barkhof F; van Berckel BNM; van der Flier WM
    Alzheimers Res Ther; 2022 Sep; 14(1):124. PubMed ID: 36057616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Digital Cognitive Biomarkers for Alzheimer's Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline.
    Bock JR; Hara J; Fortier D; Lee MD; Petersen RC; Shankle WR
    J Prev Alzheimers Dis; 2021; 8(2):123-126. PubMed ID: 33569557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Serum Triiodothyronine with Biomarkers for Alzheimer's Disease Continuum in Euthyroid Subjects.
    Ge F; Dong L; Zhu D; Lin X; Shi J; Xiao M
    J Alzheimers Dis; 2022; 85(2):605-614. PubMed ID: 34864671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.
    Silva D; Cardoso S; Guerreiro M; Maroco J; Mendes T; Alves L; Nogueira J; Baldeiras I; Santana I; de Mendonça A
    J Alzheimers Dis; 2020; 74(3):785-796. PubMed ID: 32083585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
    Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 15. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
    Ebenau JL; Timmers T; Wesselman LMP; Verberk IMW; Verfaillie SCJ; Slot RER; van Harten AC; Teunissen CE; Barkhof F; van den Bosch KA; van Leeuwenstijn M; Tomassen J; Braber AD; Visser PJ; Prins ND; Sikkes SAM; Scheltens P; van Berckel BNM; van der Flier WM
    Neurology; 2020 Jul; 95(1):e46-e58. PubMed ID: 32522798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia.
    Tan MS; Ji X; Li JQ; Xu W; Wang HF; Tan CC; Dong Q; Zuo CT; Tan L; Suckling J; Yu JT;
    Alzheimers Res Ther; 2020 May; 12(1):55. PubMed ID: 32393375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
    Blazhenets G; Frings L; Ma Y; Sörensen A; Eidelberg D; Wiltfang J; Meyer PT;
    Neurology; 2021 Mar; 96(9):e1358-e1368. PubMed ID: 33408150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of Cognitive Impairment Compatible with Early Diagnosis of Alzheimer's Disease. A Bayesian Network Model based on the Analysis of Oral Definitions of Semantic Categories.
    Guerrero JM; Martínez-Tomás R; Rincón M; Peraita H
    Methods Inf Med; 2016; 55(1):42-9. PubMed ID: 25925692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.